Since, SCLC patients universally encountered the relapse with acquire resistance to chemotherapy, we were interested to see, if FOXM1 inhibition can be used to target these resistant cells or sensitize them to cisplatin. Here, FOXM1 is linked to small cell lung carcinoma.